Upload
nguyendung
View
213
Download
0
Embed Size (px)
Citation preview
Title: Dynamic (4D) CT perfusion offers simultaneous functional and anatomical
insights into pulmonary embolism resolution.
Abstract:
Objective: Resolution and long-term functional effects of pulmonary emboli are
unpredictable. This study was carried out to assess persisting vascular bed perfusion
abnormalities and resolution of arterial thrombus in patients with recent pulmonary
embolism (PE).
Methods and materials: 26 patients were prospectively evaluated by dynamic (4D)
contrast enhanced CT perfusion dynamic pulmonary CT perfusion. Intermittent
volume imaging was performed every 1.5-1.7 seconds during breath-hold using and
perfusion values were calculated by maximum-slope technique. Thrombus load
(modified Miller score; MMS) and ventricular diameter were determined. Perfusion
maps were visually scored and correlated with residual endoluminal filling defects.
Results: The mean initial thrombus load was 13.1±4.6 MMS (3-16), and 1.2±2.1
MMS (0-8) at follow up. From the 24 CTPs with diagnostic quality perfusion studies,
normal perfusion was observed in 7 (29%), and mildly-severely abnormal in 17
(71%). In 15 patients with no residual thrombus on follow up CTPA, normal
perfusion was observed in 6, and abnormal perfusion in 9. Perfusion was abnormal in
all patients with residual thrombus on follow up CTPA. Pulmonary perfusion changes
were classified as reduced (n=4), delayed (systemic circulation pattern; n=5), and
absent (no-flow; n=5).
The right ventricle was dilated in 12/25 (48%) at presentation, and normal in all 26
follow up scans. Weak correlation was found between initial ventricular dilatation
and perfusion abnormality at follow up (r=0.15).
Conclusions: Most patients had substantial perfusion abnormality at 3-6 months post
PE. Abnormal perfusion patterns were frequently observed in patients and in regions
with no corresponding evidence of residual thrombus on CTPA. Some defects exhibit
delayed, presumed systemic, enhancement (which we have termed ‘stunned’ lung).
CT perfusion provides combined anatomical and functional information about PE
resolution.
Introduction
Pulmonary embolism (PE) is common in the Western world with an estimated
incidence of approximately 3 in 1000 population per year [1] These patients are at
increased risk of recurrent thromboembolic episodes and secondary pulmonary
hypertension with a reported first year mortality of 5-6% [2,3]. Anticoagulants are
the main recognised treatment for PE [1], but are associated with risk of
haemorrhage resulting in morbidity and mortality [4].
Despite being a common disease many aspects of the natural course of the condition
are poorly understood. It is recognised that pulmonary emboli resolve in an
inconsistent manner. The reported rate of PE resolution on computed tomography
pulmonary angiography (CTPA) varies from 40-57% in early follow ups (within 2
weeks following the acute episode), to 77-81%, after 3months of the initial PE
diagnosis [5,6].
Despite significant improvements, exclusion of pulmonary embolism by CTPA is still
restricted by its insensitivity to small, subsegmental emboli [7,8]. The speed of
resolution of clots and extent of residual perfusion defects in different patient groups
remains to be clarified. How the clot burden and rate of clot resolution relate to
persisting micro-vascular perfusion abnormalities is also unclear. Clarification of
these issues may help in risk stratification (eg. risk of subsequent pulmonary
hypertension), and in guiding treatment strategies. The aim of this study was to use
dynamic (4D) computed tomography perfusion studies (CTP) to characterise
pulmonary perfusion abnormalities and residual thrombus load in patients with
previous pulmonary embolism and to compare the finding with the thrombus load and
right heart features as measured on the presentation conventional CTPA studies. The
study hypothesis was that CTP would be superior to CTPA in the diagnosis of
residual thromboembolic disease in patients recovering from a recent episode of PE.
Methods and material:
Patients:
Following institutional approval, 26 adult patients with history of an acute PE,
confirmed on CTPA (n=25) and perfusion scintigraphy (n=1) were prospectively
recruited. Written informed consent was obtained in all cases. Perfusion CT (CTP)
studies were performed 3-6 months following the initial PE episode. Exclusion
criteria included pregnancy, inability to undergo computed tomography (CT)
scanning, renal failure (serum creatinine >250 µmol/L or estimated glomerular
filtration rate <25 mL/min), previous recruitment to the study, known contrast
allergy, unable to give informed consent, and background parenchymal lung disease
as other potential causes of perfusion changes (emphysema, fibrosis). Patients
received anti-coagulation according to local guidelines following an episode of acute
PE (Warfarin Sodium for 6 months following the episode of PE, and for lifetime in
recurrent PE). Age and gender were recorded. Patient’s body size was classified by
measuring the maximum lateral thoracic width (LTW) on AP scout films at the
cardiac-diaphragm interface (at the level of liver) [9,10]. Based on the average LTW in
our cohort, patient size was graded thin, medium, and large, when the LTW was <32cm,
32-38cm, and >38cm, respectively [10].
Image acquisition and reconstruction:
The CTP scans were performed during a single breath-hold at deep inspiration.
Shallow abdominal breathing was permitted at the end stage of acquisition in patients
who were unable to hold their breath for the entire perfusion CT data acquisition.
All CT scans were performed on a 320-multidetector computed tomography scanner
(Aquilion ONE, Toshiba Medical Systems, Nasushiobara, Japan). Low dose scout
imaging was performed to localise the thoracic structures. Intermittent volume
imaging was performed every 1.5-1.7 seconds (11-12 volumes in total) with 3
seconds delay after the start of intravenous contrast injection. Scans were performed
with 16 cm z-axis coverage (320 x 0.5-mm collimation) with the lowest section at the
level of the diaphragm, 100 kVp, 0.5s rotation, and fixed tube current 100 mA (tube
current-time product 50 mAs). Variable tube current protocol (mA boost) was used in
one patient to reduce image noise in the pulmonary arteries. This included boosting
tube current (200mAs) in 3 volumes timed with the peak of the PA enhancement, and
standard current (100mA) for the rest of 8 volumes. Toshiba’s iterative
reconstruction algorithm (Adaptive Iterative Dose Reduction 3D; AIDR-3D, strong)
was used to reconstruct 0.5mm sections from the raw data (Toshiba Medical Systems,
Nasushiobara, Japan).
A dual-head power injector (Stellant CT Injection Systems, MEDRAD, Warrendale,
USA) was used for bolus injection of 70 mL iodinated contrast agent (Iomeron 400,
Bracco SPA, Milan, Italy; 400mg/mL) via a 16G antecubital vein catheter (Vasofix,
Braun, Melsungen, Germany) at a rate of 9 mL/sec, followed by 20 mL of saline
solution at the same rate.
Post processing of dynamic contrast enhanced perfusion CT Images:
Non-rigid registration of the contrast-enhanced studies was performed using a
dedicated commercial workstation to reduce the effect of motion (Vitrea FX v6.3,
Vital Images, Minnesota, USA). For the qualitative evaluation of the perfusion,
parametric maps of perfusion were produced using the same workstation using the
Dual Input Lung Perfusion software by maximum slope method (Vitrea FX v6.3,
Vital Images, Minnetonka, USA). Regions of interest (ROIs; 5 mm diameter) were
placed in the main pulmonary artery and descending aorta to define the pulmonary
and systemic arterial input functions. Same size ROI was placed in the left atrium and
the peak enhancement time point was used to differentiate pulmonary circulation
from systemic/bronchial circulation [9]. Regions of interest were drawn in the normal
lung parenchyma away from main vascular branches, chest wall/mediastinal
structures, and dependent/atelectatic lung changes. Computation of parametric
perfusion maps was performed using the same workstation (Body Perfusion, (Vitrea
FX v6.3, Vital Images, Minnetonka, USA). The perfusion analysis range was set
from -300 HU to -1000 HU to restrict the perfusion analysis to lung parenchyma and
to exclude major vessels and the soft tissues/bones. Pulmonary blood flow (PBF;
mL/mg/min) was calculated as the maximum slope of tissue enhancement curve
divided by the maximum arterial enhancement [12]. Parametric 512 × 512 matrix
colour-coded maps of the pulmonary flow (PF) and systemic arterial flow (AF), and
pulmonary index (PI=PF/PF+AF) were generated automatically [13].
Analysis of CT pulmonary angiography (CTPA) data:
The CTPA from the acute PE presentation episode and the follow up CTPA from the
dynamic contrast enhanced perfusion study were evaluated in consensus by two
thoracic radiologists (SM and EJVB) who were blinded to patients’ details. From the
11 CT volumes, the angiogram(s) with visually densest contrast within the pulmonary
artery were used to identify residual intravascular thromboembolic material.
Overall image quality of each CTPA was rated on a 4-point scale (1: non-diagnostic;
2, fair image quality; 3: good image quality; and 4: excellent image quality). Causes
for the compromised image quality were recorded (eg. motion, image noise, beam
hardening).
Two thoracic radiologists (EJVB & JTM) objectively assessed in consensus the
pulmonary arterial obstruction using the Modified Miller Scoring system (MMS) on
both the initial CTPA and on the angiogram from the perfusion scan [14]. The
modified Miller Score (MMS) is a score of thrombus load that was originally
proposed by Miller et al. for conventional angiography and adapted for CTPA scan
[14]. The right pulmonary artery was assigned nine segmental arteries (three to the
upper lobe, two to the middle lobe, and four to the lower lobe), whereas the left
pulmonary artery was assigned seven segmental arteries (two to the upper lobe, two
to the lingula, and three to the lower lobe). Each occluded segmental pulmonary
artery that is given a score of 1. Any more proximal occlusion scores the number of
segmental branches distal to the occlusion thereby giving a MMS of 0 (no thrombus)
to 16 (thrombus in all segmental arteries or saddle embolism) [14].
Diameter of the right ventricle (RV) and left ventricle (LV) was measured on the
axial sections in the basal segment at the level of mitral valve. The RV was defined as
dilated when the RV/LV ratio was >1.
Analysis of perfusion data:
Parametric perfusion maps were objectively assessed in consensus by 2 thoracic
radiologist with expertise in CTP studies (SM & EJVB). Four patterns of pulmonary
perfusion were identified on parametric maps and were confirmed by examination of
the time-density curves in the regions of interest. The perfusion patterns were
classified as: normal perfusion, reduced perfusion (reduced enhancement slope with
delayed peak compared to normal lung; Fig. 1), systemic perfusion (delayed peak
enhancement that is synchronised with the aortic enhancement peak), and absent
(only image noise observed, no real enhancement).
The two radiologists objectively scored lobar perfusion. The agreed score was to
reflect the volume of lung in each lobe. Compared to the modified Miller’s score, the
upper lobes were assigned lower scores compared to the lower lobes since the 16cm
detector area did not cover the apices of the upper lobes in any patient. Each of the
upper lobes, right lower lobe, left lower lobe, middle lobe and the lingual were
assigned, 3, 4, 3, 2 and 1 score (total of 16 score). An objective perfusion index (OPI)
was calculated as total scored perfusion divided by 16. The lung perfusion was then
graded as: severely abnormal (OPI <0.6), moderately abnormal (OPI 0.6-0.8), mildly
abnormal (OPI >0.8), and normal (OPI =1).
Statistical analysis:
All results were expressed as mean ± standard deviation (SD) unless indicated
otherwise. Correlations between the presence of RV dilatation at presentation and
perfusion abnormality in follow up was performed using Pearson’s correlation and
expressed as r2 values. SPSS for Windows (v10.0.1) was used for all statistical
analysis.
Results:
Twenty-six consecutive patients with recent PE and a mean age of 61 (±16.5 years;
range 23-86) were recruited (male/female=16/10). The average lower thoracic
diameter was 38cm (±4.7; 30-50). Based on the lower thoracic diameter
measurements, 3, 10, and 13 patients were classified as small, medium, and large,
respectively. The average time interval between the initial CTPA (when the diagnosis
of acute PE was made) and the follow up CTP was 22 ±16 weeks.
In 3 patients, the initial CTPA had to be repeated due to poor contrast timing and
hence sub-optimal enhancement of the pulmonary arteries. The mean total dose
length product (DLP) of the initial CTPA (including the repeat scans) and the CTP
was 724±328 and 615±159 mGy·cm, respectively. The DLP for the mA boost
protocol in a borderline large patient (LTW) was 690 mGy·cm. The estimated
effective doses for the CTPA and CTP studies were 10.1±4.6 and 8.6±2.2 mSv,
respectively (conversion factor=0.014 mSv/mGy.cm). The entire lung was covered in
the standard CTPA whilst the 16cm field of view coverage did not cover the whole
upper lobe in any patient.
The quality of pulmonary angiography on the initial CTPA was rated “excellent” in
22 cases, and “good” in 3. This does not take into account that the initial CTPA in 3
patients was non-diagnostic and had to be repeated. The quality of CT pulmonary
angiogram in the CTP series was rated as “excellent” in 12, “good” in 7, “sub-optimal
but diagnostic” in 4, and non-diagnostic in 3 cases. The causes for sub-optimal
quality of the angiograms were excessive noise in 3, beam hardening in 3, and motion
in 1 case. Excessive noise and beam hardening was almost exclusively seen in larger
patients (mean LTW 39.5cm ±4). The mA boost in a patient with LTW of 37cm
resulted in excellent improvement of the quality of pulmonary angiogram, when
compared to standard mA.
The pulmonary arterial obstruction, as evaluated by the Modified Miller Scoring
system (MMS) was 13.1±4.6 (3-16) in the initial CTPA, and 1.2±2.1 (0-8) in the
angiogram from the CTP series. From the 25 diagnostic follow up CTPA, MMS was
reported as 0 in 16 patients (64%), 1-3 in 7 patients (28%), and 7-8 in 2 patients (8%)
(Fig. 2).
In 4 patients there was CT evidence of ischemic lung injury (peripheral wedge-shape
consolidation in the territory of thrombosed arteries). All the changes resolved on
follow up examination and no scaring seen.
Perfusion analysis was non-diagnostic in 2 patients, sub-optimal but diagnostic in 6
patients, and good in 18. The common causes for quality compromises were the effect
of motion on calculated perfusion values (n=7), excessive image noise (n=3), and
beam hardening (n=1). Significant image noise and beam hardening in a very large
patient with LTW of over 50cm, and significant motion that was not corrected by
image registration accounted for the non-diagnostic perfusion studies.
Figure 2 shows the percentage of patients with residual thromboembolic by
pulmonary arterial obstructive score and CT perfusion abnormality at follow up.
From the 24 patients with diagnostic CTP, normal perfusion was observed in 7 (29%)
patients (OPI=1), 10 (42%) had mild perfusion abnormalities (OPI= 0.8-0.99), 5
(20%) had moderate perfusion abnormalities (OPI=0.6-0.79), and 2 (8%) had severe
perfusion abnormalities (OPI <0.6) (Fig. 2). Perfusion was normal in 6 patients, but
abnormal in 9 patients with normal follow up CTPA. In 2 patients who had
significant residual thromboembolic material in the post treatment CT, there
was a discrepancy between the abnormalities on CTPA and CTP in both patients.
One patient with significant residual thromboembolic material (MMS=8) had severe
perfusion abnormalities (OPI=0.56), whereas the other patient with significant
residual thromboembolic material (MMS=7) showed only mild perfusion
abnormalities. In contrast, in another patient with severe perfusion abnormalities
(OPI=0.58), only mild residual thromboembolic material (MMS=2) was observed.
Figures 3-4 show examples of patients with various levels of PE resolution on CTPA
at follow up, and inconsistent level of perfusion resolution on CTP. There was weak
correlation between the MMS at presentation and perfusion abnormality at follow up
(r=0.11; Pearson's Product-Moment Correlation).
Regional pulmonary perfusion abnormalities patterns were classified as reduced
perfusion in 4 patients, significantly delayed/from systemic circulation in 5 patients,
and absent (no-flow) in 5 patients. The lung parenchyma appeared normal in areas
with delayed perfusion (termed ‘stunned’ lung). Figure 5 shows an example of
abnormally delayed pulmonary perfusion in a patient with previous PE.
Right ventricular was dilated in 12/25 (48%) on the initial CTPA, and normal in all
26 follow up scans. There was weak correlation between the presence of RV
dilatation at presentation and perfusion abnormality at follow up (r=0.15; Pearson's
Product-Moment Correlation).
During the clinical follow up period (mean 33 months; 20-54 months), 7 patients
returned with recurrent symptoms. Further investigation confirmed pulmonary
thromboembolic disease or DVT in 5 (19%): 1 new PE, 3 residual thromboembolic
material, and 2 new DVTs. All these patients had mild to moderate perfusion
abnormality on CTP. None of patients with normal CTP had recurrent presentation
during the follow up period.
Discussion
Resolution of PE is reported to be variable, ranging from 32-48% in earlier studies
[13-18] , depending on the modality used (eg. CTPA or ventilation/perfusion
scintigraphy) and the timing of the follow up (6 weeks-10.5 months) [19]. It is not
clear to what degree the reported variation was due to the limitations of imaging
techniques used in these studies. More recent studies reported a higher
resolution rate on CTPA of 81%-100% within one month from the acute episode
[20,21]. Compared to other non-invasive imaging modalities, our study shows that
dynamic (4D) CT perfusion provides comprehensive assessment of the proximal clot
burden, pulmonary perfusion, cardiac chambers, and lung parenchyma in a single
imaging episode. Combined, the above information may potentially provide a strong
tool in the evaluation of clinical outcome and treatment guidance.
As indicated earlier, previous perfusion scintigraphy studies demonstrated persistent
perfusion abnormalities even after a year and follow up scintigraphy at the
completion of the anticoagulation was recommended [22,23]. A weakness of the
scintigraphy is that it does not differentiate between new and persisting perfusion
abnormalities and as a result, a persisting perfusion defects can be misinterpreted as fresh
pulmonary embolism which may lead to unnecessary treatment and hospitalisation
[23,24]. This clearly shows the advantage of the CTP as the angiographic data embedded
in the dynamic series would differentiate acute from resolving or persistent PE.
Currently, CTPA is the standard technique for the diagnosis of acute PE. However, a
study of 1193 patients demonstrated an inconsistent relationship between clot burden
and mortality [25]. Another study only showed a relationship between proximal clot
burden and clinical deterioration [2]. These results may be partly explained by the
insensitivity of CTPA in the diagnosis of small, subsegmental emboli [7,8].
Furthermore, CTPA underestimates distal obstructive burden as shown in our results,,
which may further explain an unreliable relationship between clot burden, mortality
and clinical deterioration [2,25]. Our study demonstrated recurrence only in patients
with abnormal CTP which demonstrates the clinical relevance of the findings on CT
perfusion. Adequately powered cohorts with longer follow-up are necessary to
evaluate the sensitivity and specificity of CTP studies in the estimation of clinical
outcome.
CTP has the advantage of CTPA that it can compensate for limited spatial resolution
by incorporating dynamic information of blood flow. Previous studies showed
different patterns of vascular remodelling following pulmonary arterial obstruction
[26]. In 1847, Virchow reported that the bronchial circulation could proliferate and
sustain lung tissue distal to a pulmonary embolism [27]. An experimental model of
chronic arterial obstruction showed that at 4 months, new bronchial vessels encircled
pulmonary arteries, veins and airways, and in some instances, bronchial vessels
branched out into the parenchyma and joined with capillaries [28]. In addition to
bronchial neovascularization, intercostal arteries may participate in the
neovascularisation of the ischemic lung [29]. Overall, systemic blood flow to the lung
may increase by as much as 30% of the original pulmonary blood flow [30]. Our
hypothesis is that this mechanism accounts for the delayed perfusion pattern which
we have observed in some of these 3-6 month post PE follow up scans.
Previous imaging studies demonstrated alternative pulmonary perfusion mainly in
patients with chronic thromboembolic disorders. A study of dual energy first pass
pulmonary perfusion in 20 patients with chronic thromboembolic pulmonary
hypertension demonstrated residual perfusion in 64% of lobes with apparently
completely occluded vessels where it was suggested that the blood supply was
maintained via systemic collaterals [31]. Another dual phase dual energy study of
acute and chronic thromboembolic disorders reported late iodine enhancement
indicating systemic pulmonary supply in chronic, but not in acute thromboembolic
disease [32]. Moreover, a study of patients with chronic thromboembolic pulmonary
hypertension also demonstrated systemic supply with dilated bronchial arteries that
returned to normal after thromboendarterectomy [33].
There is evidence that understanding the pattern of perfusion has prognostic value.
Kauczor et al reported that dilated bronchial arteries on CT were a significant
predictor for survival after pulmonary thromboendarterectomy [34]. Thus, bronchial
perfusion may have a protective role in pulmonary thromboembolic disease [35].
Other experimental studies reported another protective mechanism by the reflux of
left atrial blood through the pulmonary veins to gas-exchanging tissue after
pulmonary artery ligation [36]. To our knowledge, our study is the first imaging study
to observe the systemic circulation in patients recovering from acute PE. No
associated significant bronchial dilatation was observed. In the corresponding
segments, no CT evidence of parenchymal injury/scarring was observed indicating
that alternative perfusion routes may play a protective role in these patients.
Dynamic CTP exposes patients to ionising radiation. In this study, the overall
radiation dose of the CTP was comparable to standard CTPA. Further studies,
demonstrated that by using iterative imaging reconstruction, significant radiation dose
reduction of up to four folds in smaller patients, and up to 2 fold in the medium/large
size patients can be achieved whilst diagnostic perfusion studies are achieved [10]. In
larger patients, to achieve a diagnostic CTPA, tube current modulation at the peak PA
enhancement reduces image noise and beam hardening effect.
In this cohort, one perfusion study was non-diagnostic due to excessive motion that
could not be corrected by non-rigid registration. Future improvements in registration
techniques may allow CTP in patients with poor breath hold.
We demonstrated that right heart size was not a good indicator of recovery from
obstructive consequences of an acute PE. This is not surprising since with normal
RV, 50-75% of the pulmonary vasculature must be obstructed before RV failure can
be seen [37-39]. Moreover, in the acute state, other factors such as the vasoreactive
substances released in response to the event and the baseline cardiopulmonary status
also play a role in development of RV failure [40].
There are a few technical considerations. Whilst the duration of the dynamic scan in
this protocol was sufficient to determine pulmonary and early systemic perfusion, it
may not be long enough to identify very late systemic perfusion or the full contrast
wash-out. We used a maximum slope technique to estimate perfusion, the technique
does not rely on the wash-out phenomenon. To obtain adequate vascular and tissue
opacification, 70mLs of contrast was administered. This large volume might have
potentially violated the assumption of bolus characteristics that is a prerequisite for
accurate perfusion measurements. To get the shortest and densest peak enhancement,
contrast has to be delivered directly in the pulmonary arteries, but this will not be
feasible in routine clinical practice. We used a large bore venous catheter and a high
injection rate to reduce the length of the bolus delivery. Examination of the
pulmonary artery time-density curves in all cases demonstrated a fast up-slope of
density and a relatively short peak pulmonary artery enhancement.
This study had several potential shortfalls. Firstly, CTP was only performed in the
follow-up period and not at presentation and therefore the degree of perfusion
recovery could not be assessed. Secondly the accuracy of CTP in diagnosis of
pulmonary perfusion abnormalities could not be validated by the reference technique
(catheter pulmonary angiogram) due to the invasive nature of the angiographic
procedure.
Finally, larger cohorts with long-term follow-up will be necessary to highlight the
prognostic value of CTP in patients with acute PE.
Conclusion: This study suggests a role for CTP in follow up of patients with acute
PE, enabling quantification of pulmonary arterial bed obstruction in combination with
systemic revascularisation. Phenotyping of these patients using residual thrombus
load and perfusion characterisation may allow stratification of patients at risk of long-
term complications and recurrence of PE to guide treatments options. Moreover, CTP
can differentiate new PE from persistent thromboembolic changes in patients with
recurrent symptoms.
References:
1. Anderson FA, Wheeler HB, Goldberg RJ. A population-based perspective of the
hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary
embolism: the Worcester DVT study. Arch Intern Med 1991; 151: 933–38.
2. Vedovati MC, Becattini C, Agnelli G, et al. Multidetector computed tomography
for acute pulmonary embolism: embolic burden and clinical outcome. Chest. 2012
Dec;142(6):1417-24.
3. Poulsen SH, Noer I, Møller JE, et al. Clinical outcome of patients with suspected
pulmonary embolism. A follow-up study of 588 consecutive patients. J Intern Med.
2001 Aug;250(2):137-43.
4. Mendoza V, Scharf ML. Evaluation and management of chronic pulmonary
thromboembolic disease. Hosp Pract (Minneap). 2011 Aug;39(3):50-61.
5. Stein PD, Yaekoub AY, Matta F, et al. Resolution of pulmonary embolism on CT
pulmonary angiography. Am J Roentgenol. 2010 May;194(5):1263-8.
6. Aghayev A, Furlan A, Patil A, et al. The Rate of Resolution of Clot Burden
Measured by Pulmonary CT Angiography in Patients With Acute Pulmonary
Embolism. American Journal of Roentgenology 2013 200:4, 791-797 .
7. Goodman LR, Curtin JJ, Mewissen MW, et al. Detection of pulmonary embolism
in patients with unresolved clinical and scintigraphic diagnosis: helical CT versus
angiography. AJR 1995; 164: 1369–74.
8. Ferretti GR, Bosson JL, Buffaz PD, et al. Acute pulmonary embolism: role of
helical CT in 164 patients with intermediate probability at ventilation-perfusion
scintigraphy and normal results at duplex US of the legs. Radiology 1997; 205: 453–
58.
9. McCollough CH, Bruesewitz MR, Kofler JM Jr. CT dose reduction and dose
management tools: overview of available options. Radiographics. 2006;26(2):503-12.
10. Mirsadraee S, Weir NW, Connolly S, et al. Feasibility of radiation dose reduction
using AIDR-3D in dynamic pulmonary CT perfusion. Clin Radiol. 2015 May 21. pii:
S0009-9260(15)00129-4. doi: 10.1016/j.crad.2015.04.004.
11. Yuan X, Zhang J, Ao G, , et al. Lung cancer perfusion: can we measure
pulmonary and bronchial circulation simultaneously? Eur Radiol. 2012; 22(8):1665-
71.
12. Miles KA, Griffiths MR. Perfusion CT: a worthwhile enhancement? Br J Radiol.
2003 Apr;76(904):220-31.
13. Yuan X, Zhang J, Quan C, et al. Differentiation of malignant and benign
pulmonary nodules with first-pass dual-input perfusion CT. Eur Radiol. 2013
Sep;23(9):2469-74.
14. Bankier AA, Janata K, Fleischmann D, et al. Severity assessment of acute
pulmonary embolism with spiral CT: evaluation of two modified angiographic scores
and comparison with clinical data. J Thorac Imaging. 1997 Apr;12(2):150-8.
15. Hvid-Jacobsen K1, Fogh J, Nielsen SL, et al. Scintigraphic control of pulmonary
embolism. Eur J Nucl Med 1988; 14:71–72.
16. Wartski M, Collignon MA. Incomplete recovery of lung perfusion after 3 months
in patients with acute pulmonary embolism treated with antithrombotic agents.
THESEE Study Group. Tinzaparin ou Heparin Standard: Evaluation dans l’Embolie
Pulmonaire Study. J Nucl Med 2000; 41: 1043–1048.
17. Remy-Jardin M, Louvegny S, Remy J, et al. Acute central thromboembolic
disease: posttherapeutic follow-up with spi- ral CT angiography. Radiology 1997;
203:173–180.
18. Van Rossum AB, Pattynama PM, Tjin AT, et al. Spiral CT appearance of
resolving clots at 6 week follow-up after acute pulmonary embolism. J Comput Assist
Tomogr 1998; 22:413–417.
19. Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolution of
thromboemboli in patients with acute pulmonary embolism: a systematic review.
Chest. 2006 Jan;129(1):192-7.
20. Stein PD, Yaekoub AY, Matta F, et al. Resolution of pulmonary embolism on CT
pulmonary angiography. AJR Am J Roentgenol. 2010 May;194(5):1263-8.
21. van Es J, Douma RA, Kamphuisen PW, et al. Clot resolution after 3 weeks of
anticoagulant treatment for pulmonary embolism: comparison of computed
tomography and perfusion scintigraphy. J Thromb Haemost. 2013 Apr;11(4):679-85.
22. Wartski M, Collignon M-A. Incomplete recovery of lung perfusion after 3 months
in patients with acute pulmonary embolism treated with antithrombotic agents. J Nucl
Med 2000; 41: 1043-1048.
23. Gotthardt M, Schipper M, Franzius C, Béhé M, Barth A, Schurrat T, Höffken H,
Gratz S, Joseph K, Behr TM. Follow-up of perfusion defects in pulmonary perfusion
scanning after pulmonary embolism: are we too careless? Nucl Med Commun. 2002
May;23(5):447-52.
24. Gottschalk A. The chronic perfusion defect: our knowledge is still hazy, but the
message is clear. J Nucl Med 2000; 41: 1049-1050.
25. Araoz PA, Gotway MB, Harrington JR, et al. Pulmonary embolism: prognostic
CT findings. Radiology. 2007 Mar;242(3):889-97.
26. Mitzner W, Wagner EM. Vascular remodeling in the circulations of the lung. J
Appl Physiol 2004; 97:1999–2004.
27. Virchow R. Uber die Standpunkte in den Wissenschaftlichen Medizin. Virchows
Arch 1: 1–19, 1847.
28. Michel RP, Hakim TS. Increased resistance in postobstructive pulmonary
vasculopathy: structure-function relationships. J Appl Physiol (1985). 1991
Aug;71(2):601-10.
29. Keller FS, Rosch J, Loflin TG, et al. Non- bronchial systemic collateral arteries:
significance in percutaneous embo- lotherapy for hemoptysis. Radiology 1987;164:
687–692.
30. Michel RP and Hakim TS. Increased resistance in postobstructive pulmonary
vasculopathy: structure-function relationship. J Appl Physiol 71: 601–610, 1990.
31. Hoey ET1, Mirsadraee S, Pepke-Zaba J, et al. Dual-energy CT angiography for
assessment of regional pulmonary perfusion in patients with chronic thromboembolic
pulmonary hypertension: initial experience. AJR Am J Roentgenol. 2011
Mar;196(3):524-32.
32. Hong YJ, Kim JY, Choe KO, et al. Different perfusion pattern between acute and
chronic pulmonary thromboembolism: evaluation with two-phase dual-energy
perfusion CT. AJR Am J Roentgenol. 2013 Apr;200(4):812-7.
33. Ley S, Kreitner KF, Morgenstern I, et al. Bronchopulmonary shunts in patients
with chronic thromboembolic pulmonary hypertension: evaluation with helical CT
and MR imaging. AJR Am J Roentgenol. 2002 Nov;179(5):1209-15.
34. Kauczor HU, Schwickert HC, Mayer E, et al. Spiral CT of bronchial arteries in
chronic thromboembolism. J Comput Assist Tomogr. 1994;18:855-861.
35. Rodney A. Rhoades, David R. Bell. Medical Phisiology: Principles for Clinical
Medicine – Pulmonary Embolism. Lippincott Williams & Wilkins. Page 372. (20 Jan
2012) 4th Edition.
36. Obermiller T, Lakshminarayan S, Willoughby S, et al. Influence of lung volume
and alveolar pressure on reverse pulmonary venous blood flow. J Appl Physiol
(1985). 1992 Jul;73(1):195-9.
37. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism
in patients without prior cardiopulmonary disease. Am J Cardiol 1971; 28: 288-94.
38. McIntyre KM, Sasahara AA. The ratio of pulmonary arterial pressure to
pulmonary vascular obstruction: index of preembolic cardiopulmonary status. Chest
1977; 71: 692-7.
39. Wong L, Akram A, McGurk S, Beek EVR, Reid JH, Murchison JT. Thrombus load and
Acute Right ventricular Failure in Pulmonary Embolism: Correlation and Demonstration of a
‘Tipping Point’ on CT Pulmonary Angiography. British Journal of Radiology 2012 : 78 46-
50.
40. Matthews JC, McLaughlin V. Acute right ventricular failure in the setting of
acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of
the pathophysiology, diagnosis, and management. Curr Cardiol Rev. 2008
Feb;4(1):49-59.
Figure legends:
Fig. 1. Time density curves in normal (A) and abnormally perfused (B) lung
parenchyma, 3 months after an acute pulmonary embolism episode.
Peak enhancement is reduced and delayed in the regions with abnormal
perfusion (B), when compared to well perfused lung. Regions of interests in the
normal and abnormal lungs were selected from same lobes.
Fig. 2. Percentage of patients with residual thromboembolic (A) or
perfusion abnormality (B) during on the follow up CTPA or CTP.
The graph shows whist the CTPA was reported normal in 64% of patients, only
29% had a normal CTP. The data also demonstrates that a considerable number
of patients with moderate or severe perfusion abnormality did not demonstrate
equally high modified miller score.
CTPA: CT pulmonary angiogram; CTP: CT pulmonary perfusion study.
Fig. 3. Inconsistent resolution of obstructive pulmonary embolism (PE).
A. 74 year old female presented with saddle pulmonary embolus (arrows;
modified miller’s score=16). Follow up CT pulmonary angiography and
perfusion (coronal view) demonstrated full resolution of PE (B) and normal
perfusion (C).
D: 79 year old female patient presented with multiple pulmonary embolus
(arrows; modified miller’s score =16). Follow up CT pulmonary angiography
demonstrated full resolution of PE (E) but multilobar abnormal perfusion (F;
arrows).
Fig. 4. Matched and miss-matched CTPA / CTP findings in a 76 years old
female 3 months after an acute pulmonary embolism.
Fig. A demonstrates near occlusive thrombi in the segmental branches of the
upper lobes (red and yellow arrows). The angiogram and CT performed 3
months later only demonstrates very small volume of residual webs in the right
upper lobe PA branches (red arrow), but no residual disease in the left upper
lobe branches (yellow arrow; Fig. B).
In the parametric map, black/dark blue, yellow/green, and red colour codes
represent low, moderate, and high pulmonary blood flow. CTP demonstrates
residual perfusion abnormality in the lateral segment of the right upper lobe
corresponding to the visualised webs (Fig. C; arrow). There is also significant
perfusion abnormality in the left upper lobe despite apparent revascularisation
(Fig. D; arrow). Arrowhead shows false perfusion deficit secondary to beam
hardening from the dense contrast in the superior vena cava (SVC).
CTPA: CT pulmonary angiogram; CTP: CT pulmonary perfusion study.
Fig. 5. Pulmonary CT perfusion maps of a 43 year old female 3 months
following an episode of acute pulmonary embolism. A: pulmonary arterial
perfusion map; B: systemic arterial perfusion map; C: maximum intensity
projection (MIP) of the CT pulmonary angiogram.
In the parametric map, black/dark blue, yellow/green, and red colour codes
represent low, moderate, and high pulmonary blood flow. Images demonstrate
an under-perfused segment in the left upper lobe that is later perfused by
systemic circulation (bronchial arteries). MIP images demonstrated only
enhancement from the pulmonary veins and not the pulmonary artery branches.
There was no evidence of parenchymal lung abnormality (termed ‘stunned’
lung).
Role of the Funding Source’ Role of the Funding Source:
Chest, Heart, Stroke, Scotland provided funding support to conduct this study. It
did not interfere with study design, analysis, or presentation of the data.